News

BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts

Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje AC®tissue allografts POMPANO BEACH, FLORIDA.,…

2 years ago

IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative…

2 years ago

Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference

NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri,…

2 years ago

Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.

New director brings big pharma oncology experience and biotech leadershipSAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose…

2 years ago

Better Choice Company Announces Management and Board Changes

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE American: BTTR) (the “Company” or “Better Choice”),…

2 years ago

Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s KEYTRUDA® (pembrolizumab) for treatment of…

2 years ago

Amryt Announces New Patent for Mycapssa®

Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage…

2 years ago

Smart Immune Bolsters Management Team with Medical and Technical Appointments

Smart Immune pic Dr Pierre Heimendinger and Dr Frederic Lehmann, CTO and CMO of Smart Immune. Smart Immune Bolsters Management…

2 years ago

ObsEva Announces Progress on Restructuring Initiatives

$7.6 million annual savings expected via reduction-in-force currently underway$6.2 million savings expected from assignment of legacy linzagolix program contracts to…

2 years ago

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

Plinabulin rapidly (within 24 hours) mitigates chemotherapy-induced myelosuppression by protecting bone marrow granulocyte-monocyte progenitor (GMP) stem cellsNEW YORK, Sept. 13,…

2 years ago